PALI Stock — Palisade Bio Inc.: Cash, EV, Pipeline

Share price

$1.59

Market cap

$277.1M

Cash

$125.2M

Enterprise value

$151.9M

Balance sheet

Cash	$125.2M
Debt	$0.0M
Net cash	$125.2M
Enterprise value	$151.9M
Basic shares	173.6M shares
Fully diluted shares	226.1M shares
Fully diluted market cap	$359.5M
Cash per share	$0.72

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PALI daily closes…

Loading price history…

Pipeline assets

PALI-2108

Phase 2 · Active Modality: oral prodrug (targeted PDE4 inhibition via lower-intestinal bacterial bioactivation)

Target PDE4

Partnerships Giiant: exclusive worldwide license (September 2023) to PALI-2108 and PALI-1908; development milestones and mid-single-digit royalties on sales/sublicenses. Crohn's & Colitis Foundation: up to $0.5M funding for Phase 1b program

Indications

Ulcerative colitis (moderately-to-severely active) (Phase 2)
Crohn's disease (including fibrostenotic) (Phase 1)

Catalysts

— H2 2026
— H2 2026

Status note Lead candidate. Phase 1 program completed H1 2026 (106 subjects; positive Phase 1b FSCD cohort data reported March 30, 2026). ASCENTRA-UC: randomized, placebo-controlled Phase 2 in ~204 patients (15/30 mg QD). ASCENTRA-CD Phase 2 planned.

PALI-1908

Stage not disclosed · Active

Partnerships Giiant: exclusive worldwide license (September 2023)

Status note Giiant licensed asset; no development details disclosed in excerpts.

NSI-532.IGF-1

Preclinical · Active Modality: cell therapy (preclinical)

Partnerships University of Michigan: exclusive license for continued development and licensing (October 2022); Palisade receives 50% of net licensing revenues

Status note Preclinical cell therapy investigated for prevention and treatment of Alzheimer's disease; development costs borne by the university.

LB1148

Stage not disclosed · Terminated

Status note Development terminated October 20, 2023; two of three UC Regents license agreements terminated (2015 UC license retained for Newsoara co-development).

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PALI-2108
Lead indication	Fibrostenotic Crohn's Disease
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07428096	Phase 1	Active, not recruiting	Sponsor	PALI	—	Fibrostenotic Crohn's Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Palisade Bio on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,333,000	no change	0.09%	2026-08-14
Sphera Biotech	2,257,106	+523,635	0.68%	2026-08-14
ADAR1 Capital Management	1,726,662	-538,183	0.17%	2026-08-14
Ikarian Capital	750,000	+475,022	0.26%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PALI — Palisade Bio Inc.